Study of Immunotherapy to Treat Advanced Prostate Cancer

This study has been completed.
Information provided by (Responsible Party):
Bristol-Myers Squibb Identifier:
First received: March 12, 2009
Last updated: July 23, 2014
Last verified: July 2014
The purpose of the study is to determine if advanced prostate cancer patient s that are treated with radiotherapy (RT) plus ipilimumab live longer that those treated with RT alone

Condition Intervention Phase
Prostate Cancer
Drug: Ipilimumab
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects With Castration Resistant Prostate Cancer That Have Received Prior Treatment With Docetaxel

Resource links provided by NLM:

Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:
  • Overall survival [ Time Frame: is assessed at each study visit while on treatment and every 12 weeks in the post-treatment Follow-up Phase ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Compare progression free survival (PFS) [ Time Frame: Assessed at each study visit while on treatment and every 12 weeks in the post-treatment Follow-up Phase until alternative treatment is initiated ] [ Designated as safety issue: No ]
  • Compare pain response [ Time Frame: Assessed at screening, weeks 12, 18, 24, and at the End of Treatment visit ] [ Designated as safety issue: No ]
  • Characterize safety profile [ Time Frame: Assessed at each study visit while on treatment and for 70 days following the last dose of study drug ] [ Designated as safety issue: Yes ]

Enrollment: 796
Study Start Date: May 2009
Study Completion Date: November 2012
Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Ipilimumab Drug: Ipilimumab
5 mg/ml solution, Intravenous, 10 mg/kg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase, Up to 24 weeks in Induction, 48+ weeks in the Maintenance Phase, or until Treatment Stopping Criteria are met, withdrawal of consent, lost to follow-up, death, study closure
Other Name: BMS 734016
Placebo Comparator: Placebo Drug: Placebo
Solution, Intravenous, 0 mg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase, up to 24 weeks in Induction, 48+ weeks in the Maintenance Phase, or until Treatment Stopping Criteria are met, withdrawal of consent, lost to follow-up, death, study closure


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No

For more information regarding BMS clinical trial participation, please visit

Inclusion Criteria:

  • Advanced prostate cancer
  • At least 1 bone metastasis
  • Testosterone < 50 ng/dl
  • Prior treatment with docetaxel

Exclusion Criteria:

  • Brain metastasis
  • Autoimmune disease
  • Known HIV, Hep B, or Hep C infection
  • More than 2 prior systemic anticancer regimens for prostate cancer
  • Prior treatment on BMS CA180227 for prostate cancer
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00861614

  Hide Study Locations
United States, Alabama
Southern Cancer Center
Mobile, Alabama, United States, 36608
United States, Alaska
Alaska Clinical Research Center, Llc
Anchorage, Alaska, United States, 99508
United States, Arizona
Arizona Clinical Research Center, Inc.
Tucson, Arizona, United States, 85715
United States, Arkansas
Highlands Oncology Group, P.A.
Fayetteville, Arkansas, United States, 72703
United States, California
Marsha G. Fink, Md, Inc.
Fountain Valley, California, United States, 92708
Loma Linda University Cancer Center
Loma Linda, California, United States, 92350
Usc/Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
Prostate Oncology Specialists, Inc.
Marina Del Rey, California, United States, 90292
Comprehensive Cancer Center
Palm Springs, California, United States, 92262
Va San Diego Healthcare System
San Diego, California, United States, 92161
Pacific Hematology Oncology Associates
San Francisco, California, United States, 94115
United States, Florida
Baptist Cancer Institute
Jacksonville, Florida, United States, 32207
Orlando Health, Inc
Orlando, Florida, United States, 32806
United States, Georgia
Suburban Hematology-Oncology Associates, Pc
Lawrenceville, Georgia, United States, 30046
United States, Illinois
University Of Chicago
Chicago, Illinois, United States, 60637
Cancer Care Specialists Of Central Illinois
Decatur, Illinois, United States, 62526
Edward Cancer Center
Naperville, Illinois, United States, 60540
Mid-Illinois Hematology & Oncology Associates, Ltd
Normal, Illinois, United States, 61761
United States, Iowa
University Of Iowa Hospitals And Clinics
Iowa City, Iowa, United States, 52242
Siouxland Hematology-Oncology Assoc., Llp
Sioux City, Iowa, United States, 51101
United States, Kansas
Hutchinson Clinic, Pa
Hutchinson, Kansas, United States, 67502
United States, Kentucky
Kentucky Cancer Clinic
Hazard, Kentucky, United States, 41701
United States, Maryland
The Bunting-Blaustein Cancer Research Building
Baltimore, Maryland, United States, 21231
Frederick Memorial Hospital Regional Cancer Therapy Center
Frederick, Maryland, United States, 21701
United States, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02115
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
United States, Missouri
Kansas City Veterans Affairs Medical Center
Kansas City, Missouri, United States, 64128
St Johns Medical Research Institute, Inc.
Springfield, Missouri, United States, 65807
United States, New York
Weill Cornell Medical College
New York, New York, United States, 10065
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
United States, North Carolina
Raleigh Hematology Oncology Associates
Raleigh, North Carolina, United States, 27607
United States, Ohio
Gabrail Cancer Center
Canton, Ohio, United States, 44718
University Of Cincinnati
Cincinnati, Ohio, United States, 45267
United States, Oregon
Providence Portland Medical Center
Portland, Oregon, United States, 97213
United States, Pennsylvania
St. Luke'S Hospital & Health Network Laboratory
Bethlehem, Pennsylvania, United States, 18015
Va Pittsburgh Healthcare System
Pittsburgh, Pennsylvania, United States, 15240
Associates In Hematology & Oncology, P.C.
Upland, Pennsylvania, United States, 19013
United States, South Carolina
Musc Hollings Cancer Center
Charleston, South Carolina, United States, 29445
United States, Texas
Center For Oncology Research & Treatment, P.A.
Dallas, Texas, United States, 75230
The Center For Cancer And Blood Disorders
Fort Worth, Texas, United States, 76104
Northwest Cancer Center
Houston, Texas, United States, 77090
The University Of Texas Md Anderson Cancer Center
Houston, Texas, United States, 77030
United States, Utah
Huntsman Cancer Institute
Salt Lake City, Utah, United States, 84112
United States, West Virginia
Edwards Comprehensive Cancer Center
Huntington, West Virginia, United States, 25701
Local Institution
Caba, Buenos Aires, Argentina, 1417
Local Institution
Capital Federal, Buenos Aires, Argentina, 1426
Local Institution
Rosario, Santa Fe, Argentina, 2000
Local Institution
Rosario, Santa Fe, Argentina, S2000DSK
Local Institution
San Miguel De Tucuman, Tucuman, Argentina, T4000IAK
Local Institution
San Miguel De Tucuman, Tucuman, Argentina, 4000
Local Institution
Buenos Aires, Argentina, 1019
Local Institution
Buenos Aires, Argentina, 1120
Local Institution
Buenos Aires, Argentina, C1280AEB
Local Institution
Buenos Aires, Argentina, C1426ANZ
Local Institution
Cordoba, Argentina, X5002AOQ
Local Institution
Cordoba, Argentina, X5006HBF
Local Institution
La Rioja, Argentina, 5300
Australia, Victoria
Local Institution
Box Hill, Victoria, Australia, 3128
Local Institution
Frankston, Victoria, Australia, 3199
Local Institution
Heidelberg, Victoria, Australia, 3084
Australia, Western Australia
Local Institution
Subiaco, Western Australia, Australia, 6008
Local Institution
Salzburg, Austria, 5020
Local Institution
Wien, Austria, 1090
Local Institution
Brussels, Belgium, 1090
Local Institution
Bruxelles, Belgium, 1000
Local Institution
Bruxelles, Belgium, 1200
Local Institution
Roeselare, Belgium, 8800
Local Institution
Fortaleza, Ceara, Brazil, 60430
Local Institution
Curitiba, Parana, Brazil, 80440
Local Institution
Ijui, Rio Grande Do Sul, Brazil, 98700000
Local Institution
Porto Alegre, Rio Grande Do Sul, Brazil, 90430
Local Institution
Porto Alegre, Rio Grande Do Sul, Brazil, 90610
Local Institution
Curitiba, Sao Paulo, Brazil, 80530
Local Institution
Divinopolis, Sao Paulo, Brazil, 35500
Local Institution
Mogi Das Cruzes, Sao Paulo, Brazil, 08730
Local Institution
Sao Paulo, Brazil, 09060
Local Institution
Sao Paulo, Brazil, 05403
Canada, Quebec
Local Institution
Greenfield Park, Quebec, Canada, J4V 2H1
Local Institution
Montreal, Quebec, Canada, H2L 4M1
Local Institution
Temuco, Araucania, Chile
Local Institution
Santiago, Metropolitana, Chile, 7510032
Local Institution
Santiago - Independencia, Metropolitana, Chile
Local Institution
Santiago De Chile, Metropolitana, Chile, 7650635
Local Institution
Vi?a Del Mar, Valparaiso, Chile
Local Institution
Monteria, Cordoba, Colombia
Local Institution
Bogota, Colombia
Czech Republic
Local Institution
Brno, Czech Republic, 656 91
Local Institution
Hradec Kralove, Czech Republic, 500 05
Local Institution
Liberec, Czech Republic, 460 63
Local Institution
Aalborg, Denmark, 9000
Local Institution
Aarhus, Denmark, 8000
Local Institution
Herlev, Denmark, 2730
Local Institution
Kobenhavn O, Denmark, 2100
Local Institution
Odense C, Denmark, 5000
Local Institution
Besancon Cedex, France, 25030
Local Institution
Bordeaux, France, 33076
Local Institution
Clermont-ferrand, France, 63000
Local Institution
Marseille Cedex 20, France, 13915
Local Institution
Pointe A Pitre, France, 97159
Local Institution
Villejuif Cedex, France, 94800
Local Institution
Berlin, Germany, 14197
Local Institution
Bonn, Germany, 53127
Local Institution
Eschweiler, Germany, 52249
Local Institution
Mannheim, Germany, 68167
Local Institution
Wuppertal, Germany, 42103
Local Institution
Athens, Greece, 115 28
Local Institution
Budapest, Hungary, 1122
Local Institution
Gyula, Hungary, 5700
Local Institution
Kaposvar, Hungary, 7400
Local Institution
Kecskemet, Hungary, 6000
Local Institution
Dublin 7, Dublin, Ireland
Local Institution
Tallaght, Dublin, Ireland, DUBLIN 24
Local Institution
Dublin, Ireland
Local Institution
Beer Jacob, Israel, 70300
Local Institution
Beer-sheva, Israel, 84101
Local Institution
Haifa, Israel, 31096
Local Institution
Tel Aviv, Israel, 64239
Local Institution
Tel Hashomer, Israel, 52621
Local Institution
Meldola (fc), Italy, 47014
Local Institution
Milano, Italy, 20132
Local Institution
Napoli, Italy, 80131
Local Institution
Rimini, Italy, 47900
Local Institution
Siena, Italy, 53100
Local Institution
Sondrio, Italy, 23100
Local Institution
Df, Distrito Federal, Mexico, 06720
Local Institution
Mexico, Distrito Federal, Mexico, 07760
Local Institution
Acapulco, Guerrero, Mexico, 39570
Local Institution
Guadalajara, Jalisco, Mexico
Local Institution
Cuernavaca, Morelos, Mexico, 62290
Local Institution
Aguascalientes, Mexico, 20234
Local Institution
Puebla, Mexico, 72270
Local Institution
Amsterdam, Netherlands, 1066 CX
Local Institution
Mb Amsterdam, Netherlands, 1007MB
Local Institution
Arequipa, Peru, AREQUIPA54
Local Institution
Lima, Peru, 18
Local Institution
Lima, Peru, 34
Local Institution
Lima, Peru, L-27
Local Institution
Lima, Peru, LIMA 11
Local Institution
Olsztyn, Poland, 10-228
Puerto Rico
Ponce School Of Medicine
Ponce, Puerto Rico, 00716
Local Institution
Bucharest, Romania, 011172
Local Institution
Romania, Romania, 400015
Local Institution
Suceava, Romania, 720237
Russian Federation
Local Institution
Moscow, Russian Federation, 115478
Local Institution
Moscow, Russian Federation, 117997
Local Institution
Moscow, Russian Federation, 129128
Local Institution
Obninsk, Russian Federation, 249036
Local Institution
St Petersburg, Russian Federation, 197758
Local Institution
Barcelona, Spain, 08208
Local Institution
Barcelona, Spain, 08035
Local Institution
Benidorm-alicante, Spain, 03501
Local Institution
Madrid, Spain, 28922
Local Institution
Santiago De Compostela, Spain, 157706
Local Institution
Valencia, Spain, 46009
United Kingdom
Local Institution
Chelmsford, Essex, United Kingdom, CM1 7ET
Local Institution
Cardiff, Glamorgan, United Kingdom, CF14 2TL
Local Institution
Manchester, Greater Manchester, United Kingdom, M20 4BX
Local Institution
Scunthorpe, Lincolnshire, United Kingdom, DN15 7BH
Local Institution
Nottingham, Nottinghamshire, United Kingdom, NG5 1PB
Sponsors and Collaborators
Bristol-Myers Squibb
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  More Information

Additional Information:
No publications provided by Bristol-Myers Squibb

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Bristol-Myers Squibb Identifier: NCT00861614     History of Changes
Other Study ID Numbers: CA184-043  2008-003314-97 
Study First Received: March 12, 2009
Last Updated: July 23, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms processed this record on February 04, 2016